Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis.
Abrams
Charles S
CS
Hematology-Oncology Division, University of Pennsylvania, Philadelphia 19104-4283, USA. abrams@mail.med.upenn.edu
Cines
Douglas B
DB
D000077284:Abciximab; D000409:Alanine / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D015551:Autoimmunity; D001550:Benzamidines / Q000009:adverse effects; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000209:etiology / Q000276:immunology; D011759:Pyrrolidines / Q000009:adverse effects; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology* / Q000276:immunology; D013927:Thrombosis / Q000517:prevention & control
D000911:Antibodies, Monoclonal; D001550:Benzamidines; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011759:Pyrrolidines; C120234:orbofiban; D000409:Alanine; C091295:xemilofiban; D000077284:Abciximab